Contraceptive Technology Update
RSSArticles
-
‘Talk. Test. Treat.’ Aimed at Syphilis
There are more reported cases of primary and secondary syphilis in the United States now than there have been in more than 20 years. The Centers for Disease Control and Prevention has issued a call to action to reverse the trend.
-
Task Force Issues Draft Guidance on Ovarian Screening
The U.S. Preventive Services Task Force has issued a draft recommendation statement on ovarian screening, finding that the potential harms of screening outweigh the benefits.
-
Vasectomy Poses Minimal Prostate Cancer Risk
A new systematic review and meta-analysis of three decades of evidence concludes that vasectomies are associated with minimal risk of prostate cancer.
-
Research Finds Many Women Who Receive IUD for Emergency Contraception Continue Use
Sixty-seven percent of women offered long-acting option were using it at one year.
-
Research Identifies Potential New Gonorrhea Treatments
About 820,000 new gonococcal infections occur in the United States each year, with some 570,000 appearing in young people ages 15-24. In an effort to stem the tide of infection, science has identified a potential new treatment, which uses a peptide to disrupt an enzyme the microbe needs to respirate.
-
Concerns About Privacy May Prevent Some Youth From Getting STI Tests
Many on parents’ health plans would not get care due to privacy issues.
-
Can College Health Centers Improve Access to Abortion Care?
College health centers may be a student’s only access to healthcare, especially on campuses in rural areas.
-
New Test May Aid in Clinical Management of Vaginitis
A molecular diagnostic test that accurately distinguishes among the three most common causes of vaginitis — bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis — earned Food and Drug Administration market authorization in October 2016 for use by diagnostic laboratories.
-
While Many Pharmacies Have EC, Can Teens Access It?
In 2013, the Food and Drug Administration removed age restrictions on emergency contraception (EC), allowing it to be sold over the counter to all consumers. However, results of a new study indicate that barriers to and disparities in access for adolescents still exist.
-
Data Indicate Efficacy of Liletta IUD for Four Years’ Use
Four-year data from the ongoing multicenter, U.S.-based pivotal trial of the 52 mg Liletta levonorgestrel-releasing intrauterine device (IUD) indicate its safety and efficacy for four years of use in nulliparous and parous women, as well as in non-obese and obese women.